Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-05-01T06:14:31.124Z Has data issue: false hasContentIssue false

105 - Thrombomodulin

from PART II - ENDOTHELIAL CELL AS INPUT-OUTPUT DEVICE

Published online by Cambridge University Press:  04 May 2010

Marlies Van de Wouwer
Affiliation:
Department for Transgene Technology and Gene Therapy, VIB, and the Center for Transgene Technology and Gene Therapy (CTG), K.U. Leuven, Belgium
Edward M. Conway
Affiliation:
Department for Transgene Technology and Gene Therapy, VIB, and the Center for Transgene Technology and Gene Therapy (CTG), K.U. Leuven, Belgium
William C. Aird
Affiliation:
Harvard University, Massachusetts
Get access

Summary

Thrombin has far-reaching effects in a variety of biological systems, including coagulation, inflammation, cell survival, and cell proliferation. Modulation of the dynamic production of this key protease is essential to maintain homeostasis during development and, in adults, under a variety of pathophysiological conditions. The crucial importance of thrombin has prompted intense studies over the past few decades to characterize the molecular pathways that regulate its functional expression. The remarkable insight of several scientists led to the discovery of thrombomodulin (TM) (1), a key regulator of thrombin's activities, a predominantly vascular endothelial cell (EC) cofactor in a physiologically relevant natural anticoagulant system, and a modulator of inflammation and cell proliferation, with links to innate immunity.

THROMBOMODULIN IS A MASTER SWITCH THAT PREVENTS BLOOD CLOTTING

The discovery of TM (1,2), elegantly recounted by Esmon and Owen (1), emanated from evidence in the 1960s of the existence of a circulating thrombin-activated protein – now referred to as activated protein C (APC) – and the identification and isolation of its precursor, protein C (PC) (3). PC is a vitamin-K–dependent plasma protein, synthesized in the liver and circulating as a biologically inactive species. Activation of PC by thrombin requires TM as a cofactor (4) (Figure 105.1), which accelerates the reaction over 1,000-fold. APC, in turn, suppresses further thrombin generation through the proteolysis of coagulation factors Va and VIIIa, facilitated by the cofactor, protein S (PS). Not only does TM affect the generation of APC but, when complexed with TM, thrombin's entire substrate specificity is changed such that it no longer functions as a procoagulant molecule. For example, thrombin-TM is not able to activate platelets or factor V, or to cleave fibrinogen.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Thrombomodulin
    • By Marlies Van de Wouwer, Department for Transgene Technology and Gene Therapy, VIB, and the Center for Transgene Technology and Gene Therapy (CTG), K.U. Leuven, Belgium, Edward M. Conway, Department for Transgene Technology and Gene Therapy, VIB, and the Center for Transgene Technology and Gene Therapy (CTG), K.U. Leuven, Belgium
  • Edited by William C. Aird, Harvard University, Massachusetts
  • Book: Endothelial Biomedicine
  • Online publication: 04 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511546198.106
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Thrombomodulin
    • By Marlies Van de Wouwer, Department for Transgene Technology and Gene Therapy, VIB, and the Center for Transgene Technology and Gene Therapy (CTG), K.U. Leuven, Belgium, Edward M. Conway, Department for Transgene Technology and Gene Therapy, VIB, and the Center for Transgene Technology and Gene Therapy (CTG), K.U. Leuven, Belgium
  • Edited by William C. Aird, Harvard University, Massachusetts
  • Book: Endothelial Biomedicine
  • Online publication: 04 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511546198.106
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Thrombomodulin
    • By Marlies Van de Wouwer, Department for Transgene Technology and Gene Therapy, VIB, and the Center for Transgene Technology and Gene Therapy (CTG), K.U. Leuven, Belgium, Edward M. Conway, Department for Transgene Technology and Gene Therapy, VIB, and the Center for Transgene Technology and Gene Therapy (CTG), K.U. Leuven, Belgium
  • Edited by William C. Aird, Harvard University, Massachusetts
  • Book: Endothelial Biomedicine
  • Online publication: 04 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511546198.106
Available formats
×